Dr Guy H. Jerusalem, MD, PhD
Head of Medical Oncology in the Department of Medicine
Director of the Breast Clinic, Sart-Tilman University Hospital
Professor in Medical Oncology, University of Liège in Belgium

“Clinical Update: Metastatic Breast Cancer”

Wednesday, December 2, 2015

Hôpital général du Lakeshore
Cafeteria conference room
(ENGLISH TALK)
8:00 à 9:00

Jewish General Hospital
Room E-711
(ENGLISH TALK)
12:00 à 13:00 Visioconference: http://telesantemcgill.ca
nathalie.huard@mcgill.ca

Hôpital Notre-Dame
Amphithéâtre Deschamps
(FRENCH TALK)
17:00 à 18:00 Live on the Web! www.vpsolution.tv/ppio
Problems/Questions: 514 813-4510

Learning Objectives
• To gain a better understanding of endocrine resistance in HR+ advanced breast cancer and provide strategies to overcome it
• To understand the sequencing of treatment options for the different types of post-menopausal patients with ER+/HER2 negative advanced breast cancer
• To review best strategies for AE management, with oral targeted agents (BRAWO data)

This event has received an educational grant from:
Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lilly Oncology, Lundbeck, Merck, Novartis, Pfizer, Roche